I already did, and the opinion I got is that unless this drug can show the levels of proteinuria reductions (>50%) and complete/partial remission rates seen with standard of care immunosuppression like steroids, the dimx drug may have limited use. We already know this is a class of drug ccr2 I, that doesn’t have good track record and been shown to be a bit mediocre in kidney diseases with proteinuria.
I already did, and the opinion I got is that unless this drug...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $214.5M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 39.3¢ | 38.5¢ | $275.1K | 709.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49999 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 200000 | 2 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |